ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
May 13 2015 - 5:15PM
Business Wire
Presentations to include initial findings with
Company’s mirvetuximab soravtansine (IMGN853) for ovarian cancer
and results from Roche’s MARIANNE trial with Kadcyla®
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today provided information on
ImmunoGen-related presentations to take place at the 2015 American
Society of Clinical Oncology (ASCO) annual meeting being held May
29-June 2 in Chicago, IL.
ImmunoGen’s mirvetuximab soravtansine is the first ADC to target
folate receptor alpha (FRα), which is highly expressed on many
ovarian cancers and on other types of solid tumors. The ASCO
presentations will be on the initial findings from the Phase I
expansion cohort assessing this ADC as a single agent for the
treatment of patients with FRα-positive platinum-resistant ovarian
cancer (abstract #5518) and the dose-finding results to date with a
weekly dosing schedule compared with a once every three week
schedule (abstract #5558).
Abstract #5518
- Title: “Preliminary single agent
activity of IMGN853, a folate receptor alpha (FRα)-targeting
antibody-drug conjugate (ADC), in platinum-resistant epithelial
ovarian cancer (EOC) patients (pts): Phase I trial.”
- Gynecologic Cancer Poster Session: May
30, 1:15-4:45pm CT (S Hall A, Board #76), followed by oral
discussion with highlights during the Gynecologic Cancer Poster
Discussion Session 4:45-6:00pm CT (E354b).
Abstract #5558
- Title: “Phase 1 study of IMGN853, a
folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC)
in patients (Pts) with epithelial ovarian cancer (EOC) and other
FRA-positive solid tumors.”
- Gynecologic Cancer Poster Session: May
30, 1:15-4:45pm CT (S Hall A, Board #116)
There will be several presentations on Roche’s Kadcyla®
(ado-trastuzumab emtansine), which uses ImmunoGen’s ADC technology,
including one on the data from the MARIANNE Phase III trial
(Abstract #507).
- Title: “Phase III, randomized study of
trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab +
taxane (HT) for first-line treatment of HER2-positive MBC: Primary
results from the MARIANNE study.”
- Breast Cancer Oral Abstract Session:
June 1, 10:12-10:24am CT (N Hall B1)
Additional information can be found on the 2015 ASCO annual
meeting website.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024